Table 1.
Summary of studies using BNCT by disease site.
| Study | Number of patients | Boron carrier | Outcomes |
|---|---|---|---|
| Glioblastoma Multiforme | |||
| Chanana et al. (4) | 38 | BPA-F | Median OS: 13 months Median time to progression: 31.6 months |
| Henriksson et al. (5) | 30 | BPA-F | Median OS: 14.2 months Median time to progression: 5.8 months |
| Kawabata et al. (6) | 11 | Combination BPA/BSH with EBRT | Median OS: 23.5 months |
| Kageji et al. (7) | 23 | BSH | Median survival: 19.5 months 5 year OS: 9.1% |
| Miyatake et al. (8) | 167 | BPA | Median OS: 10.8 months (recurrent) Median OS: 15.6 months (newly diagnosed) |
| Head and Neck (Definitive) | |||
| Kankaanranta et al. (9) | 30 | BPA-F | Response rate: 76% Median PFS: 7.5 months 2 year OS: 30% |
| Head and Neck (Recurrent) | |||
| Kato et al. (10) | 26 | BPA alone or BPA and BSH |
Median survival: 13.6 months |
| Suzuki et al. (11) | 62 | BPA alone or BPA and BSH |
Median survival: 10.1 months Response rate: 58% 2 year OS: 24.2% |
| Koivunoro et al. (12) | 79 | BPA-F | Complete response rate: 36% 2 year LRPFS 38% 2 year OS 21% |
| Wang et al. (13); Wang et al. (14) | 23 | BPA-F | 2 year locoregional control: 28% 2 year OS: 47% |
| Cutaneous Melanoma | |||
| Menendez et al. (15) | 7 | BPA | Response rate: 69% |
BNCT, boron neutron capture therapy; BPA, boronophenylalanine; BSH, sodium borocaptate; EBRT, external beam radiation therapy; LRPFS, locoregional progression free survival; OS, overall survival; PFS, progression free survival.